On June 25th, Merck announced that its PD-1 inhibitor, Pembrolizumab (trade name: Koreda®), has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment in combination with trastuzumab, fluorouracil, and platinum containing drugs for fully validated detection and evaluation of locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma patients expressing PD-L1 (Comprehensive Positive Score (CPS) ≥ 1). The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-811.